AP01
Phase 2Small molecule
AP01 is one of 29 small molecule programs targeting Pulmonary Fibrosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Cytoxan
BBaxter Healthcare Corporation
Approved
Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
MS Contin
Merck & Co.Phase 3
Tracleer
Johnson & JohnsonPhase 3
Jascayd
Boehringer IngelheimPhase 3
Inhaled Prostacyclin
United TherapeuticsPhase 3
Danocrine
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AP01. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAvalyn Pharma Inc.